Additionally, 23% of the mutations in our study (p = 3.1 × 10−10; OR = 3.8) were found in genes that are recurrently mutated in human myeloma (defined as a mutation present in at least 2 patients [36]) including the BCL6 interacting factor Dnah9 [37, 38] and the immunomodulating factor Irf2bp2 (Supplementary Table 2) [39, 40]. This evidence concerns the gene DNAH9 and plasma cell myeloma.